22 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that it is now a member and will hold a Board position on the Council on Radionuclides and Radiopharmaceuticals, Inc (CORAR), a trade association…
Sydney, Australia 25 August 2021 Clarity Pharmaceuticals lists on the ASX today under code CU6 after raising $92.0 million at $1.40 per share, equating to an indicative market capitalisation of approximately $358.6million (on an undiluted basis) at the Offer price. Clarity is an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing…
Sydney, Australia 25 August 2021 – Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has been dosed with 64Cu SAR-bisPSMA in the dosimetry phase of the SECuRE clinical trial (NCT04868604)1…
Sydney, Australia 10 August 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been dosed in the 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer. Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very excited to…
Sydney, Australia 28 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient recruitment has commenced with the opening of the…
Sydney, Australia 20 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that its 64Cu SAR-bisPSMA clinical trial in patients with confirmed prostate cancer is open for recruitment at two sites, GenesisCare CTA Medical Clinic, Perth and Nepean Hospital, Sydney. Clarity’s Executive Chairman,…
Notice of General Meeting July 2021 (click to browse) Virtual Meeting Online Guide (click to browse)
Sydney, Australia 8 June 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that its clinical trial of 64/67Cu SARTATE™ for paediatric patients with neuroblastoma has been expanded to include five sites in the U.S. “We are very excited to expand into additional clinical…
BELOIT, Wis. and Sydney, Australia – May 25, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Master Supply…
Sydney, Australia 11 May 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Shaemus Gleason as Executive Vice President U.S. Operations as the company expands its presence, clinical trials, and operations in the U.S. Shaemus joins Clarity from Bayer’s Oncology Strategic…